Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | ||||||
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | ||||||
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | ||||||
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | ||||||
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support. Add lines 7 through 10 | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2022 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2022 |
(iii) Distributable Amount for 2022 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2022 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2022 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2022: | ||||
| a From 2017....... | ||||
| b From 2018....... | ||||
| c From 2019....... | ||||
| d From 2020....... | ||||
| e From 2021....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2022 distributable amount | ||||
|
i
Carryover from 2017 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2022 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2022 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2022, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2022. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2023. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2018..... | ||||
| b Excess from 2019..... | ||||
| c Excess from 2020..... | ||||
| d Excess from 2021..... | ||||
| e Excess from 2022..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990 - ORGANIZATION'S MISSION | THE PRIMARY TAX-EXEMPT PURPOSE OF THE CLEVELAND VA MEDICAL RESEARCH AND EDUCATION FOUNDATION, A 501(C)(3) MEDICAL RESEARCH FOUNDATION ESTABLISHED IN ACCORDANCE WITH TITLE 38, SUBCHAPTER IV-RESEARCH AND EDUCATION CORPORATIONS, SECTIONS 7361-7368, IS TO SUPPORT BIOMEDICAL AND CLINICAL RESEARCH AS WELL AS TO PROVIDE HEALTH-RELATED EDUCATIONAL ACTIVITIES IN CONJUNCTION WITH THE LOUIS STOKES CLEVELAND DEPARTMENT OF VA MEDICAL CENTER (VAMC). RESEARCH SPONSORED BY THE CLEVELAND VA MEDICAL RESEARCH AND EDUCATION FOUNDATION BENEFITS VETERANS TREATED AT THE LOUIS STOCKS CLEVELAND VAMC AND THE GENERAL PUBLIC BY ADVANCING KNOWLEDGE IN THE DIAGNOSIS AND TREATMENT OF DISEASE AND DISABILITY. EDUCATION PROGRAMS SUPPORTED BY THE CLEVELAND VA MEDICAL RESEARCH AND EDUCATION FOUNDATION HELP DISSEMINATE THE RESULTS OF RESEARCH SO THEY MAY BE TRANSLATED TO CLINICAL PRACTICE, PROVIDE HOSPITAL STAFF WITH TRAINING IN THE LATEST TREATMENTS, AND HELP PATIENTS UNDERSTAND AND MANAGE THEIR MEDICAL CONDITIONS. |
| FORM 990, PAGE 2, PART III, LINE 4A | DR. ELIZABETH FINE SMILOVICH, GERIATRICIAN AT THE CLEVELAND VA RECEIVED A SUBAWARD FROM THE ARNOLD FOUNDATION THROUGH UNIVERSITY OF PENNSYLVANIA TO STUDY THE REPLICATION OF THE TRANSITIONAL CARE MODEL (TCM) VIA A RANDOMIZED CONTROL TRIAL CONDUCTED ACROSS FOUR HEALTH SYSTEMS WITH A TOTAL OF 1,600 ENROLLED PATIENTS. THIS STUDY WAS ALSO SUPPORTED IN PART BY THE VA HEALTH SERVICES RESEARCH AND DEVELOPMENT SERVICE. THE PURPOSE OF THE TRANSITIONAL CARE MODEL IS TO EXPLORE THE ADVANCED PRACTICE REGISTERED NURSES (APRNS) ROLE WITH PATIENTS AND THEIR FAMILY CAREGIVERS AFTER DISCHARGE FROM THE HOSPITAL, AND TO SEE IF THEIR INVOLVEMENT IN POST-DISCHARGE MEDICAL MANAGEMENT MAY IMPROVE THE PATIENTS' EXPERIENCE AND ENHANCE THEIR HEALTH OUTCOMES. THE STUDY ENROLLED PARTICIPANTS 65 YEARS AND OLDER AND WHO HAD BEEN ADMITTED TO THE HOSPITAL WITH PNEUMONIA OR A HISTORY OF HEART FAILURE AND COPD OR WHOSE SYMPTOMS SUGGESTED A NEW HEART FAILURE OR COPD DIAGNOSIS. ONCE A PARTICIPANT SIGNED THE CONSENT FORM, THEY WERE RANDOMLY ASSIGNED INTO THE CONTROL GROUP OR INTERVENTION GROUP. THE CONTROL GROUP WAS GIVEN A QUESTIONNAIRE WHILE IN THE HOSPITAL AND 90-DAYS POST HOSPITAL DISCHARGE. PARTICIPANTS IN THE INTERVENTION GROUP WERE GIVEN THE SAME QUESTIONNAIRE BUT ALSO ASSIGNED AN APRN TO COORDINATE THEIR CARE FOR 60-90 DAYS AFTER DISCHARGE. THE APRN WORKED WITH THE PARTICIPANTS VA HEALTH CARE TEAM TO ASSESS THEIR MEDICAL NEEDS, COORDINATE SERVICES, AND ASSIST IN DESIGNING AND IMPLEMENTING THE PLAN OF CARE. THE APRN ALSO ATTENDED THE PARTICIPANTS FIRST AND SOMETIMES SUBSEQUENT FOLLOW-UP APPOINTMENTS POST-DISCHARGE. DR. FINE SMILOVICH AND HER TEAM ENROLLED 194 SUBJECTS INTO THIS STUDY OVER A TWO-YEAR PERIOD. INITIAL ANALYSIS IS SHOWING PROMISING RESULTS FROM THE APRN INVOLVEMENT. PRELIMINARY DATA SHOWS THAT ONLY ABOUT 16% OF PARTICIPANTS IN THE INTERVENTION GROUP HAD REHOSPITALIZATIONS 30-DAYS POST DISCHARGE COMPARED TO THE CONTROL GROUP AT ABOUT 22% REHOSPITALIZATION RATE. |
| FORM 990, PAGE 2, PART III, LINE 4B | DR. KATARINA GREER, GASTROENTEROLOGIST AT THE CLEVELAND VA, RECEIVED A DOD PEER REVIEWED CANCER RESEARCH PROGRAM (PRCRP) IMPACT AWARD IN 2021. THE GRANT ENTITLED "NONENDOSCOPIC SCREENING TO IMPACT ESOPHAGEAL CANCER IN VETERANS" IS A THREE-YEAR GRANT THAT STARTED IN EARLY 2022. THIS IS THE FOUNDATION'S FIRST CLINICAL DOD AWARD. BACKGROUND: ESOPHAGEAL ADENOCARCINOMA (EAC) HAS INCREASED MORE THAN 6-FOLD IN THE PAST FOUR DECADES. THE INCORPORATION OF A NON-ENDOSCOPIC DETECTION METHOD IN PRIMARY CARE PRACTICE WILL INCREASE THE POSITIVE PREDICTIVE VALUE OF EGD AND INCREASE THE DETECTION OF BARRETT'S ESOPHAGUS (BE). THIS STUDY WILL AIM TO DETERMINE SENSITIVITY, SPECIFICITY, AND POSITIVE PREDICTIVE VALUE OF ESOCHECK SAMPLING DEVICE ESOGUARD (DNA MARKER PANEL LABORATORY DIAGNOSTIC TEST) PERFORMED IN ROUTINE PRACTICE FOR DETECTING BE IN AN AT- RISK POPULATION. THE SECOND AIM OF THE STUDY IS TO COMPARE THE YIELD OF DETECTED BE USING AN ESOCHECK/ESOGUARD STRATEGY VERSUS STANDARD EGD ALONE STRATEGY IN ROUTINE PRACTICE IN AT-RISK POPULATIONS AT THE CLEVELAND VA SHORT TERM IMPACT: THE EXPECTED OUTCOME OF THE PROPOSED WORK IS THE GATHERING OF DETAILED INFORMATION ABOUT THE TEST PERFORMANCE CHARACTERISTICS, I.E. SENSITIVITY, SPECIFICITY, POSITIVE AND NEGATIVE PREDICTIVE VALUE. SHOULD THE SCREENING TEST PERFORM WELL, ESOCHECK/ESOGUARD TEST WOULD BE PRODUCED ON A LARGER SCALE, ITS MOLECULAR DIAGNOSTICS PROCESS WOULD BE AUTOMATED, DRIVING COSTS OF THE SCREENING DEVICE DOWN. TEST INDICATION COULD BE EXPANDED TO ALL OBESE PATIENTS OLDER THAN 50 WITHOUT A HISTORY OF CHRONIC GERD, EXPLORING THE PREVALENCE OF BE/ECA IN ASYMPTOMATIC INDIVIDUALS. LONG TERM IMPACT: FOLLOWING SUCCESSFUL VALIDATION OF THE PROPOSED NON- INVASIVE SCREENING METHOD, THE TEST COULD BE USED AS TRIAGING TOOL FOR ENDOSCOPY IN ESOPHAGEAL CANCER SCREENING. IMPLEMENTATION OF AN OFFICE BASED UNSEDATED TEST WOULD ALSO ENABLE SCREENING OF A BROADER POPULATION. PATIENTS WITH POSITIVE MOLECULAR TESTING, SUGGESTIVE OF THE PRESENCE OF METHYLATED DNA WOULD UNDERGO DIAGNOSTIC UPPER ENDOSCOPY. THIS TEST WOULD LIKELY IDENTIFY BE, BE WITH DYSPLASIA, OR EARLY ESOPHAGEAL CANCER. PATIENTS WITH DYSPLASTIC TISSUE WOULD BE ELIGIBLE FOR ENDOSCOPIC TREATMENT METHODS, INCLUDING ENDOSCOPIC MUCOSAL RESECTION OR RADIOFREQUENCY ABLATION. PATIENTS WITH DEEPER TISSUE INVOLVEMENT COULD STILL PROCEED TO SURGERY, RECEIVE CHEMOTHERAPY OR RADIATION. TREATMENT OPTIONS OTHER THAN PALLIATIVE CARE WOULD BE AVAILABLE LEADING TO IMPROVED DISEASE-FREE SURVIVAL. |
| FORM 990, PAGE 2, PART III, LINE 4C | DR. VEIZI, CHIEF OF PAIN MEDICINE, AT THE CLEVELAND VA, RECEIVED AN NIH SUBAWARD THROUGH JOHNS HOPKINS UNIVERSITY FOR A MULTICENTER STUDY TITLED "A SEQUENCED-STRATEGY FOR IMPROVING OUTCOMES IN PATIENTS WITH KNEE OSTEOARTHRITIS PAIN" SKOAP STUDY. SKOAP IS A NATIONAL STUDY FUNDED BY THE HELPING ADDICTION LONG-TERM INITIATIVE OR NIH HEAL INITIATIVE. BACKGROUND: THE PURPOSE OF THE SKOAP STUDY (CLINICALTRIALS.GOV-NCT04504812) IS TO COMPARE DIFFERENT TREATMENT OPTIONS FOR PEOPLE LIVING WITH KNEE OSTEOARTHRITIS PAIN. THE GOAL IS TO REDUCE PAIN AND IMPROVE FUNCTION USING CONSERVATIVE TREATMENT AND IF NEEDED, NON-SURGICAL PROCEDURAL TREATMENTS. PROCESS: THIS STUDY HAS TWO PHASES 2700 PATIENTS AND BOTH PHASES COMPARE DIFFERENT NON-SURGICAL TREATMENTS FOR KNEE OSTEOARTHRITIS PAIN. PHASE 1: PEOPLE WHO PARTICIPATE ARE RANDOMIZED TO ONE OF THREE GROUPS: 1. BEST PRACTICES 2. DULOXETINE (AN ORAL MEDICATION USED TO IMPROVE PAIN) OR 3. ONLINE COPING SKILLS TRAINING. PHASE 2: PEOPLE WHO PARTICIPATE ARE RANDOMIZED INTO ONE OF THREE GROUPS. 1. JOINT INJECTION 2. NERVE BLOCK OR 3. NERVE ABLATION. THE IMPORTANCE OF SKOAP: THERE IS AN URGENT PUBLIC HEALTH NEED TO FIND CLINICALLY PROVEN TREATMENTS TO IMPROVE QUALITY OF LIFE AND REDUCE RELIANCE ON OPIOIDS, FOR LONG-TERM PAIN MANAGEMENT FOR PATIENTS SUFFERING FROM KNEE OA. THIS EFFECTIVENESS TRIAL WILL COMPARE AVAILABLE TREATMENTS FOR PAIN REDUCTION AND FUNCTIONAL IMPROVEMENT IN PATIENTS WITH KNEE OSTEOARTHRITIS. THE RESULTS CAN LEAD TO IMPROVED PATIENT SELECTION AND INFORM EVIDENCE- BASED GUIDANCE BY OFFERING WELL-TESTED, EFFECTIVE, NON-OPIOID ALTERNATIVES. DR. VEIZI IS A MEMBER OF THE NATIONAL EXECUTIVE COMMITTEE FOR THE SKOAP STUDY. SINCE JOINING THE STUDY, DR. VEIZI AND HIS TEAM, INCLUDING MS. STOUT, CNP AND MS. MECKLEY, RN AS RESEARCH COORDINATORS, DAMIEN KETER, PT AND DR. GANDHI AS SITE CO-I, HAVE BEEN RECOGNIZED MULTIPLE TIMES FOR THEIR IMPRESSIVE WORK IN EXCEEDING ENROLLMENT GOALS. |
| FORM 990, PAGE 2, PART III, LINE 4D | OTHER RESEARCH AND SERVICE ACTIVITIES. |
| FORM 990, PAGE 6, PART VI, LINE 11B | FORM 990 IS DISTRIBUTED TO THE BOARD OF DIRECTORS AND IS REVIEWED, DISCUSSED, AND APPROVED. |
| FORM 990, PAGE 6, PART VI, LINE 12C | THE ORGANIZATION IS REQUIRED BY THE U.S. DEPARTMENT OF VETERANS AFFAIRS TO MONITOR ITS CONFLICT OF INTEREST POLICY THROUGH ANNUAL CONFLICT OF INTEREST AND ETHICS CERTIFICATIONS. |
| FORM 990, PAGE 6, PART VI, LINE 15A | THE ORGANIZATION HAS ONLY ONE COMPENSATED OFFICER, THE EXECUTIVE DIRECTOR. AN ANNUAL REVIEW OF COMPENSATION FOR SIMILAR NPO RESULTS IN THE APPLICATION OF A COST OF LIVING INCREASE IN THE CLEVELAND AREA. THE AMOUNT OF THE EXECUTIVE DIRECTOR'S SALARY THUS CALCULATED IS INCLUDED IN THE BUDGET WHICH IS APPROVED BY THE BOARD OF DIRECTORS. |
| FORM 990, PAGE 6, PART VI, LINE 19 | THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE FOR INSPECTION UPON WRITTEN REQUEST. THE ORGANIZATION DOES NOT GENERALLY MAKE ITS ORGANIZING DOCUMENTS OR CONFLICT OF INTEREST POLICY AVAILABLE TO THE GENERAL PUBLIC. |
| FORM 990, PART IX, LINE 11G | CONSULTING FEES 2,370 45,508 0 OUTSIDE STUDY FEES 1,666,812 0 0 PAYROLL PROCESSING FEES 5,497 3,594 0 SUBJECT PAYMENT 32,156 0 0 TOTAL 1,706,835 49,102 0 |
| Software ID: | |
| Software Version: |